Dewulf, Jonatan
Flieswasser, Tal
Delahaye, Tim
Vangestel, Christel
Miranda, Alan
de Haard, Hans
Jacobs, Julie
Smits, Evelien
Van den Wyngaert, Tim
Elvas, Filipe http://orcid.org/0000-0001-9790-3369
Clinical trials referenced in this document:
Documents that mention this clinical trial
Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models
https://doi.org/10.1186/s41181-023-00194-3
Documents that mention this clinical trial
Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models
https://doi.org/10.1186/s41181-023-00194-3
Documents that mention this clinical trial
Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models
https://doi.org/10.1186/s41181-023-00194-3
558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study
https://doi.org/10.1136/jitc-2022-sitc2022.0558
Documents that mention this clinical trial
Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models
https://doi.org/10.1186/s41181-023-00194-3
Documents that mention this clinical trial
Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models
https://doi.org/10.1186/s41181-023-00194-3
Documents that mention this clinical trial
Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models
https://doi.org/10.1186/s41181-023-00194-3
Funding for this research was provided by:
University of Antwerp (BOF DOCPRO: FFB180183, BOF ‘Startkrediet’: FFB210263)
Article History
Received: 29 March 2023
Accepted: 20 April 2023
First Online: 24 April 2023
Declarations
:
: Experimental procedures and protocols were performed following European Directive 86/609/EEC Welfare and Treatment of Animals and were approved by the local ethical committee (2017-70, University of Antwerp, Belgium).
: Not applicable.
: Authors TD, HdH and JJ are employees of argenx BV. No other potential conflicts of interest relevant to this article exist.